N/A
Completed N=37
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
Source: ClinicalTrials.gov NCT00456014 ↗Enrolled (actual)
37
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Remission of Depressive Symptoms — 14; 14 participants
Summary
This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Remission of Depressive Symptoms |
14; 14 | — |
| SECONDARY Remission of Depressive Symptoms - Tricyclic Phase |
1; 3 | — |
| SECONDARY Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase |
45.46; 30.01 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of current major depressive disorder
- Currently depressed
- Subjects must be generally healthy with no significant medical problems, anemia/blood loss, or cardiac abnormalities
- Likely to tolerate medication washout
- Capacity to provide informed consent
- Off of anti-coagulant/anti-platelet treatment for 10 days
- Willing to travel to Brookhaven for PET scanning
Exclusion Criteria
- Current abuse of or dependence on alcohol or another substance (>6 months remission okay)
- History of other major psychiatric disorders such as bipolar, schizophrenia, schizoaffective; anorexia or bulimia in past year
- First degree family history of schizophrenia if subject is under 33
- Unable/unwilling to discontinue all psychotropic medication that affects the serotonin system
- Pregnant, breastfeeding, or planning to become pregnant during the study
- A medical contraindication to antidepressants
- Dementia
- Prior head trauma with evidence of cognitive impairment
- Well-documented failure of two or more SSRI AND tricyclic antidepressant (TCA) trials of adequate dose and duration
- Metal implants, pacemaker, metal protheses or orthodontic appliance, the presence of shrapnel
- Current past, present, or anticipated exposure to radiation
- Actively suicidal
- Lifetime history of glaucoma
- Lack of response to >2 trials of antidepressant monotherapy of adequate dose and duration
- Claustrophobia
Data sourced from ClinicalTrials.gov (NCT00456014). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.